pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest decis
number use chart shown review section includ share trade
head into/out earn histor case dont time dens text feel free
skim
gener outlook remain prefer larg cap pick strong track record
beat/rais around earn updat note unpredict base factor
rebates/donut hole insur plan turnov said histor decent move
around earn result see chart
transit year set next wave diversif
upadacitinib risankizumab elagolix might grind share especi
said compani still engin posit newsflow year beats/rais
share repurchas potenti even deem prudent list price hike humira
imbruvica start year help provid growth
also written rova-t stemcentrx platform there still plenti
come term increment data rova-t basket studi potenti early-
stage clinic program ye could get addit rova-t strategi updat
think fda review document competitor jak inhibitor baricitinib lly/inci
actual favor abbv upadacitinib wont full clariti
regulatori review complet
earn call guid adjust ep adjust ep
growth growth midpoint report imbruvica us profit
ex-u revenu previous laid long-term guidanc earn
call top-tier revenu growth double-digit earn growth total nomin
sale potenti risk-adjust
dollar weaken versu euro yen swiss franc y/i
dollar across currenc vs euro vs yen vs chf roughli
revenu deriv ou countri compani toward low end dollar
weak beneficiari sector
consensu vs evr isi estim
focal point
elagolix pdufa endometriosi like adcom watch durat use
label
upadacitinib read-through baricitinib adcom apr
upadacitinib select-earli vs methotrex data
risankizumab bla file psoriasi potenti fda approv
imbruvica phoenix dlbcl data
imbruvica illumin unfit cll/sll data
venclexta potenti snda approv broad r/r cll popul
venclexta snda submiss aml potenti fda approv late
addit rova-t triniti sclc data
possibl addit rova-t basket trial data
rova-t nivo and/or r/r sclc data
colorect cancer ovarian cancer data
veliparib vela non-squam nsclc data
strong posit multipl derisk late stage asset elagolix announc two addit
posit trial uterin fibroid quarter endometriosi pdufa push back
follow request addit liver function test unlik adcom delay sound
precautionari light esmya liver toxic associ confirm
clinic signific relev liver enzym elev elagolix trial elagolix like
approv endometriosi solid efficaci data well focus
monitor requir durat use lupron recommend month dose
high dose elagolix show bone miner densiti bmd reduct
studi endometriosi hormon add-back prevent bmd loss
on-going estim primari complet date oct mo data clinicaltri gov
given specif guidanc data would avail note possibl label
augment like time-frame data perhap
competit program myovant obseva move along well market
sizeabl readili support three blockbust opportun believ
humira expect continu grow us biosimilar entri recent settl
samsung/biib allow us launch june month jan
biosimilar free-to-launch date eu biosimilar enter start oct contact us
want list humira biosimilar develop estim eros
peak brand still grow
bearish investor believ chang pharmaceut suppli chain somehow
neutral humira power formulari posit although dont see trend
would make possibl time soon even express confid maintain
humira presenc interchang biosimilar plan avail
remain seen that accur negoti discounts/reb pbm
specialti pharmaci
risankizumab upadacitinib pois off-set inevit humira revenu eros
risankizumab bla file psoriasi expect like approv given consist
efficaci result upadacitinib demonstr superior humira select-compar trial
rate dvt/pe continu remain consist background rate ra popul
close monitor baricitinib adcom comprehens clinic program clear dose-
respons efficaci select-mono trial noteworthi differenti baricitinib
yield potenti market edg bolster market access leadership posit
unlik baricitinib doesnt appear platelet elev issu upadacitinib select- earli
upadacitinib vs methotrex expect present report
upadacitinib trial mod/sev atop dermat show quicker onset action
dupix advantag small molecul could make major player
market dvt/pe seen pivot trial expect initi later year
imbruvica phoenix result diffus larg b-cell lymphoma report data studi
compar r-chop alon vs r-chop imbruvica regimen set treatment length
durat use imbruvica month set contrast cll patient treat
progress imbruvica year
far compani note littl market impact launch azn calquenc
market share nrx refractori imbruvica
new formul imbruvica launch late feb caus spike nrx script
imbruvica previous oral capsul avail recommend daili dose
cll patient would like take capsules/day although evid
emerg patient could get take lower dose new formul singl
tablet price regardless dose patient take
chang cost patient reduc dose expens
venclexta approv broader r/r cll market expect imbruvica share
r/r set adopt venclexta may gradual imbruvica use shift earli data
gener aml promis consult fda file
like approv late year ahead schedul
rova-t triniti result setback full result howev triniti gave
two cycl therapi patient could retreat progress possibl limit
redos drove lack durabl respons also possibl addit dose adc-
relat tox accumul meru studi mainten sclc expect
data rova-t continu dose omit everi cycl addit stemcentrx adc
ovarian cancer colorect cancer expect data
mavyret launch hcv appear robust base im script help drive near-term
revenu ep growth howev experi leav us reluct place much
emphasi product consid limit long-term growth dynam overal hcv
here share trade histor around earn report left column nbi
adjust red mean trade green mean trade blue move
histor product/lin item specif perform vs consensu
follow chart highlight product specif perform past quarter red miss
green beat blue in-lin
here latest statu abbv key product
product track
cgvhd fda decis fda approv soongvhd data cll w/ gazyva dlbcl w/ r-chop data mcl later interim shine mcl mcl later abbvpotenti interim nhl interim nhl data readout dlbcl unfit cll/sll interim data cll studi young fit watch wait patient on-going data evalu mono/combo br/fcr potenti snda submiss mcl dlbcl potenti snda submiss mcl dlbcl murano r/r cll murano r/r cll murano r/r cll readout come monthssnda submiss r/r cll eu potenti approv venclexta r/r cllsnda submiss r/r cll complet expect approv cll studi on-going inc comb imbruvica older/comorbid data on-going studi initi studi mainten data aml mm submit snda aml potenti approv late myeloma aml on-going data inhl dlbcl later pivot mm ra data later ra studi ye next month beyond biolog failur cdmard ra pivot come month select beyond select-monotherapi launch ra pivot select-compar select- ra pivot trial remain nda submiss select-compar data eular june cd start u/c start cd ddw start start cd later a/ uc ad start uc start giant cell arter ad uc giant cell arter report full ad aad meet ad later ad on-going start u/c soonprogress studi cd uc ad ad later on-going psoriat arthriti cd also evalu psoriasi studi later launch psoriasi studi later launch psoriasi studi later file launch bla psoriasi bla psoriasi expect fda approv cd start start cd soon start u/c cd start uc cd uc cd expect begin studi uc start start start triniti triniti normal yr surviv file triniti sclc triniti triniti sclc top-line data present data chemo rova-t opdivo yervoy sclc start taho sclc combo i/o data meru/taho data combo i/o data meru/taho ongoingneuroendocrin basket studi data basket studi data sclc sclc sclc otherposs addit data neuroendocrin basket studi gbm data potenti gbm gbm potenti gbm data potenti gbm trial on-going file gbmongo gbm endometriosi file endometriosi endometriosi present asrm congress end octprior review grant pdufa expect fibroid toward fibroid fibroid uterin fibroid top-line data announc us e/m could opioid pain build market educatemavyretus/eu approv approv approv expect greatest impact multi-billioncfroom improv benefit pt move toward mid phase novel program clinic alreadi clinic program clinic sever addit move clinic yearmultipl program advanc multipl modal target data colorect cancer data ovarian colorect cancer ovarian cancer data neoadjuv mbc nsclc advanc tnb nsclc fail data nsclcvela data nsclc compani reportsrova-telagolixabbv product outlook upadacitinibrinsakizumab april
perform us revenu project use previous describ analysi methodolog
best guess recogn /scrip calcul volatil plan turn
copays/donut hole reset would caution over-reli project
humira imbruvica look come slightli consensu mavyret come
line consensu
histor report price increas key productsnew imbruvica formul
productproduct detailswac price chang effect dateproductproduct detailswac price chang effect oral tablet mg packag size mavyret oral tablet mg packag size pak oral tablet therapi pack mg packag size oral capsul mg packag size ea venclexta venclexta oral tablet mg packag size ea lupron depot intramuscular kit mg packag size ea lupronhumirahumira subcutan pre-filled syring kit packag qti intramuscular solut mg/ml packag size ml imbruvicasourc wolter kluwer clinic drug inform inc wkcdi copyright wolter kluwer clinic drug inform inc wkcdi endors data view opinion find express herein document materi prepar behalf evercor isi employe april
here matter key line item head earli
track key emerg product commentari past earn call
product/lin itemfocuscommenthumiraaddit biosimilar settlement impact biosimilar launch ou salesno major driver chang humira sale earli although impact biosimilar entranc phoenix data dlbcl studi combo gazyva competit threat phoenix data dlbcl present unlik cll dlbcl treatment fix durat month calquenc azn current nrx mcl major treat patient refractori imburvica elagolixpdufa endometriosi focu monitor requirement/dur treatment high dose competit dynamicspdufa date push follow request addit liver function test delay sound precautionari light esmya confirm clinic signific relev liver enzym elev elagolix trial adcom seem unlik given discuss close examin bone miner densiti monitor requir high dose possibl restrict durat treatment venclextapotenti approv broader r/r cll set murano trial snda potenti approv amlgradu expans r/r cll imbruvica move toward cll rova-taddit triniti data combo data io r/r sclc poss addit basket trial data written rova-t triniti data still increment data basket studi earli data stemcentrx asset risankizumabbla file psoriasi expect consist efficaci data across multipl psorasi studi risankizumab pois anoth immunolog blockbust select-earli data ra vs methotrex adcom baricitinibsafeti profil thu far look fairli consist select trial major dvt/pe issu appear dose depend effect howev well continu monitor rate dvt/pe last studi gbm on-going support file gbm base studi meet primari endpoint os howev highlight gbm differ tmz optun rail recurr gbm approv settingmacro topicsformulari updat biosimilar competit threatssourc compani report evr isi analyst commentari area focu april
line revenueglob oper sale fx oper growth doubl growth growth rheum doubl digit derm gi cd/uc share ps hs major formulari chang leader across categoriesrobust market ra spa psoriasi crohn uc posit vari high singl digit tender time inventori half month half month half monthimbruvicaglob oper cll market share leader across line cll market cll market sharestrong del ger/frn/ashar loss price erosionmor performancecontribut contract cycl esp sharepar acccess across cover live usclos neg partnership account partnership partnership partnership account exchang hedg leverag rule equiti comp pronounc compani reportshumiraviekiramavyretduopaabbv histor quarter perform commentaryadjust tax rateadjust epscreonadj gross marginadjust salesadjust sg salesoper margin april
track forward guidanc detail past quarter
also examin annual guidanc given begin year earn call past
year compar actual result end year
growth oper fx minim fx compound-annual-growth-rate fx oper fx oper fx fx annual mid-high teensmid/high teensmid/high teensmid/high teen teenshigh teenslow teen yoyhumira ou annual mid-singl digitmid-singl fx approach mid-mid-singlepeak qmid-singl volum fx mid singlemid-single-digit yoyimbruvica qhigh-singl prior qimbruvica w/w annual product annual androgen creon mid-high singl lupron synagi synthroid flatmavyret deliv multi-billion peakglob hcv equal split us ou market creon growth duodopa androgel zinbryta synagi lupron synthroid flatgross margin weak usd may impact qlower synagi expect sale sale margin expens tax rate increas next year approach ep y/i non-cash non-cash sourc compani reportsannu guidanc start year unless indic april
also look see guidanc chang across key product segment chang
annual guidanc guidanc earningsactu result actual vs guidanc earningsactu result actual vs guidanc earningsactu result actual vs guidanc earningsactu result actual vs guidancerevenu growth fx rangehigh-teen oper rangehumira annual high rangehumira ou annual mid-singl rangemid-singl oper rangeimbruvica w/w rang rangemid-singl rangecreonhigh singl digit doubl digit singl singl digit rangedoubl digit rangedoubl digit rangedoubl digit rangegross margin ranger sale rangesg sale rangeoper margin exchang rate rangeinterest expens rangeadjust tax rate ep compani transcript press releaselow doubl digit global mid-teen guidanc guidanc guidanc earn guidanc vs guidanc midpoint guidanc earn guidanc vs guidanc midpoint guidanc earn guidanc vs guidanc midpoint guidanc earn guidanc vs guidanc midpoint rang revenu growth fx fxn/amid-teen oper fxdecreas fx annual high teensn/amid-high ou annual mid-singl digitn/amid-singl digitno changepeak w/w digitincreasemid-singl digitno declineflatincreaseflatno changeflatno changeflatno changeflatno changeflatno changecreonhigh singl digit growthlow doubl digit growthincreasehigh singl digitdecreasehigh singl digitno digit growthdoubl digit growthno changedoubl digit growthno changedoubl digit growthno changegross margin sale sale changeoper margin exchang rate expens changeadjust tax rate increas next yearsdecreaseadjust ep y/i increasesourc compani transcript press releaselow doubl digit global mid-teen global increas april
im chart includ key product
monthli sale hcv drug
weekli trx androgel creon
monthli sale androgel creon
lupron
im monthli sale month month chang year year chang
follow chart show larg biopharma histor valuat rang metric highlight
red arrow set view garpi nameamong best growth matur
biopharma compani attract multipl
n/m last n/a n/a n/a n/a factset tax adjust adjust reflect sni jvev/fcfev/ebitdaroicstock perform vs nbi absolut price-to-earnings estimatesr salesprice/ earn ad year ep compound-annual-growth-rate estim year ep compound-annual-growth-rate estimatesep yr compound-annual-growth-rate deltap/e/gconsensu ptcurrent priceconsensu rate buy sell average analyst pt vs currentlast performancelast performancefcf yielddividend yieldavg ep beat last quarter ep beat last quartersshort interestev mm comparison metric larg cap biotechcompanymkt cap mm april
help
last last factset tax adjustedev mm comparison metric pharmacompanymkt cap mm consensu ptcurrent priceconsensu rate buy sell average analyst pt vs currentlast performancelast performancefcf yielddividend yieldshort intereststock perform vs nbi absolut price-to-earnings estimatesr salesprice/ earn ad year ep compound-annual-growth-rate estim year ep compound-annual-growth-rate estimatesep yr compound-annual-growth-rate deltap/e/gev/fcfev/ebitdaro april
deriv pt use dcf discount rate termin growth rate discount
rate standard rate appli across derisk biopharma compani reflect believ appropri return
sharehold termin growth rate reflect durabl natur compani biolog franchis
clearli humira domin product model still assum repres total model revenu
current framework biosimilar adopt chang humira method use patent fall multipl
biosimilar launch simultan creat pent-up precipit impact sale share could suffer rova-t
elagolix import pipelin program either stumbl share could see modest downsid
articl articl
time dissemin april et
analyst josh schimmer steven breazzano maneka mirchandaney ami liu shenston huang primarili respons
prepar research report attest follow view opinion render research report reflect
person view subject compani issuer part research analyst compens directli
relat specif recommend view research report
